Your browser doesn't support javascript.
loading
HIV-1 Vpu restricts Fc-mediated effector functions in vivo.
Prévost, Jérémie; Anand, Sai Priya; Rajashekar, Jyothi Krishnaswamy; Zhu, Li; Richard, Jonathan; Goyette, Guillaume; Medjahed, Halima; Gendron-Lepage, Gabrielle; Chen, Hung-Ching; Chen, Yaozong; Horwitz, Joshua A; Grunst, Michael W; Zolla-Pazner, Susan; Haynes, Barton F; Burton, Dennis R; Flavell, Richard A; Kirchhoff, Frank; Hahn, Beatrice H; Smith, Amos B; Pazgier, Marzena; Nussenzweig, Michel C; Kumar, Priti; Finzi, Andrés.
Afiliação
  • Prévost J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address: jeremie.prevost@umontreal.ca.
  • Anand SP; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
  • Rajashekar JK; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Zhu L; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Richard J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Goyette G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Medjahed H; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Gendron-Lepage G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Chen HC; Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA.
  • Chen Y; Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
  • Horwitz JA; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Grunst MW; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Zolla-Pazner S; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Haynes BF; Duke Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, NC 27710, USA; Consortium for HIV/AIDS Vaccine Development (CHAVD), Duke University, Durham, NC 27710, USA.
  • Burton DR; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology,
  • Flavell RA; Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06519, USA.
  • Kirchhoff F; Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.
  • Hahn BH; Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6076, USA.
  • Smith AB; Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA.
  • Pazgier M; Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
  • Nussenzweig MC; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
  • Kumar P; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Finzi A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: andres.finzi@um
Cell Rep ; 41(6): 111624, 2022 11 08.
Article em En | MEDLINE | ID: mdl-36351384
ABSTRACT
Non-neutralizing antibodies (nnAbs) can eliminate HIV-1-infected cells via antibody-dependent cellular cytotoxicity (ADCC) and were identified as a correlate of protection in the RV144 vaccine trial. Fc-mediated effector functions of nnAbs were recently shown to alter the course of HIV-1 infection in vivo using a vpu-defective virus. Since Vpu is known to downregulate cell-surface CD4, which triggers conformational changes in the viral envelope glycoprotein (Env), we ask whether the lack of Vpu expression was linked to the observed nnAbs activity. We find that restoring Vpu expression greatly reduces nnAb recognition of infected cells, rendering them resistant to ADCC. Moreover, administration of nnAbs in humanized mice reduces viral loads only in animals infected with a vpu-defective but not with a wild-type virus. CD4-mimetics administration, known to "open" Env and expose nnAb epitopes, renders wild-type viruses sensitive to nnAbs Fc-effector functions. This work highlights the importance of Vpu-mediated evasion of humoral responses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_enfermedades_transmissibles Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV Limite: Animals / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_enfermedades_transmissibles Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV Limite: Animals / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2022 Tipo de documento: Article
...